Clinical utility of subcutaneous hirudins

American Journal of Health-System Pharmacy

Volumn 60, Issue 20 SUPPLIMENT 5, 2003, Pages

  Deitcher, Steven R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Anticoagulants; Desirudin; Heparin; Lepirudin; Thrombocytopenia; Toxicity

Indexed keywords

ANTITHROMBIN; HEPARIN; HIRUDIN DERIVATIVE;

ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; UNITED STATES; VEIN THROMBOSIS;

ANTITHROMBINS; CLINICAL TRIALS; HEPARIN; HIRUDINS; HUMANS; INJECTIONS, SUBCUTANEOUS; THROMBOCYTOPENIA; UNITED STATES; VENOUS THROMBOSIS;

EID: 1542709664     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.1093/ajhp/60.suppl_5.s27     Document Type: Conference Paper

References (16)

1. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994; 74:1-23.
2. Nowak G. Pharmacology of recombinant hirudin. Semin Thromb Hemost. 2002; 28:415-23.
3. Refludan package insert. Wayne, NJ: Berlex Laboratories; 2002.
4. Deitcher SR, Carman TL. Heparin-induced thrombocytopenia: natural history, diagnosis, and management. Vasc Med. 2001; 6:113-9.
5. Schiele F, Lindgaerde F, Eriksson H et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. Thromb Haemost. 1997; 77:834-8.
6. Neuhaus K-L, Molhoek GP, Zeymer U et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol. 1999; 34:966-73.
7. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101:125-30.
8. Huhle G, Hoffmann U, Hoffmann I et al. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res. 2000; 99:325-34.
9. Eriksson BI, Ekman S, Kälebo P et al. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996; 347:635-9.
10. Eriksson BI, Kälebo P, Anthymyr BA et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin. J Bone Joint Surg Am. 1991; 73:484-93.
11. Nurmohamed MT, Rosendaal FR, Buller HR et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 1992; 340:152-6.
12. Eriksson BI, Wille-Jørgensen P, Kälebo P et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997; 337:1329-35.
13. Greinacher A, Eichler P, Albrecht D et al. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood. 2003; 101:2617-9.
14. Eichler P, Friesen H-J, Lubenow N et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000; 96:2373-8.
15. Begelman SM, Deitcher SR. Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report. J Thromb Thrombolysis. 2002; 13:183-5.
16. Andreescu ACM, Cushman M, Hammond JM et al. Trousseau's syndrome treated with long-term subcutaneous lepirudin (case report and review of the literature). J Thromb Thrombolysis. 2001; 11:33-7.